Your selection

Innovation / 23.01.2024
Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access to Eckert & Ziegler's high-purity Actinium-225, a radionuclide for use in developing the next generation of therapeutic radiopharmaceuticals.

Ac-225 has emerged as a highly promising active agent for the treatment of cancer. The radioisotope releases potent alpha particles with high energy and short penetration depths, allowing for precise targeting of tumor cells, including hard-to-reach micro-metastases, while minimizing impact on surrounding healthy tissue. Based on its potential, clinical and industry experts expect a substantial increase in Ac-225 demand in the coming decade.

“We are delighted to have forged a supply collaboration with Full-Life Technologies, dedicating ourselves to facilitating their journey in clinical development,” said Dr Harald Hasselmann, CEO of Eckert & Ziegler. “Historically, limited Ac-225 supply has impeded progress in both clinical research and commercial applications. With the establishment of our new Ac-225 production facility, we aim to significantly increase access to this important radionuclide, with ramp up at the new facility occurring in the second half of the year.”

Ac-225 constitutes an essential element within our portfolio of therapeutic compounds, including our lead candidate, Ac-FL-020 for the treatment of metastatic castration-resistant prostate cancer,” stated Philippe van Put, General Manager of Full-Life Technologies Europe. “Securing access is imperative for advancing our development and clinical research efforts. Eckert & Ziegler brings great expertise and more than three decades of experience as a radioisotope specialist in support of our ambitious development initiatives.”

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

About Full-Life Technologies
Full-Life Technologies Limited ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The Company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

Source: Press Release EZAG
Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

Overview News

News Buch Berlin

From cell biology to CRISPR/Cas – new knowledge for schools

The Life Science Learning Lab at the Berlin-Buch research campus offers both school students and teachers the opportunity to immerse themselves in science. This year, the facility celebrates its 25th ...

more ...

ERC grants Berlin scientists € 2.5 million each

Neuroscientists Gary Lewin and James Poulet at the Max Delbrück Center for Molecular Medicine have won highly coveted and competitive ERC Advanced Grants to study pain and the neural mechanisms that u...

more ...

The Protein Expert

Prof. Dr. Fan Liu from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has recently received several awards for her contributions to the field of cross-linking mass spectrometry.

more ...

Events Buch Berlin

23.04.2024, 11:00
Kostenlose öffentliche Fahrrad-Codierung

Das Präventionsteam des Polizeiabschnittes 14 ist auf dem Campus Berlin-Buch und codiert kostenlos Fahrräder

more ...

06.05.2024, 09:00
Realtime PCR und digital PCR Kurs

Der RealTime PCR und Digital PCR Kurs richtet sich an erfahrene PCR Anwender*innen und an Einsteiger*innen. Wichtige PCR Grundlagen werden erörtert, bevor die RealTime PCR besprochen und Genexpression...

more ...

22.06.2024, 16:00
Lange Nacht der Wissenschaften 2024

Save the date!

more ...

This website is supported by: